TAFRO Syndrome Associated with EBV and Successful Triple Therapy Treatment: Case Report and Review of the Literature

Table 1

Summary of the most common treatment regimens for those diagnosed with TAFRO syndrome.

Case report	Age (years)/gender	TAFRO-directed treatment			General outcome
		1st line	2nd line	3rd line
Simons, 2016	22/M	TCZ	TCZ, rituximab, etoposide		Clinical improvement
Tedesco, 2015	21/F	Prednisone, TCZ	Rituximab, cyclophosphamide, vincristine, prednisone		Clinical improvement
Takai et al., 2010 [17]	39/M	Methylprednisolone, prednisolone			Clinical improvement
	38/M	Prednisolone			Clinical improvement
Koduri et al., 2014 [15]	14/M	CHOP 6	Thalidomide		Persistent lymphadenopathy, no edema or ascites
Kubokawa et al., 2014 [7]	15/M	Methylprednisolone	TCZ, IVIG		Cytokine levels decreased by 4 months
Ozawa et al., 2014 [10]	48/F	IVIG	Steroids	Rituximab	Resolution of thrombocytopenia and marrow fibrosis
Kawabata et al., 2013 [9]	47/F	Prednisone	TCZ, steroids		Improvement of IL-6 levels, no signs of disease recurrence
Inoue et al., 2013 [8]	49/F	Dexamethasone	Cyclosporine A		Resolution of thrombocytopenia and marrow fibrosis
Iwaki et al., 2013 [11]	43/F	Methylprednisolone	Rituximab, TCZ, steroids		Improvement of thrombocytopenia and anasarca
Masaki et al., 2013 [12]	57/F	Methylprednisolone	CHOEP		Died from septic shock
	73/M	Prednisolone			Died from multiorgan failure
Takai et al., 2010 [17]	47/F	CHOP, prednisolone	Prednisolone (maintenance)		Clinical improvement
	56/M	Methylprednisolone, IVIG	Cyclosporin A		Improved platelet count, edema, ascites
	49/M	Methylprednisolone, IVIG			Died from multiorgan failure
	53/F	Prednisolone	Prednisolone, cyclophosphamide		Clinical improvement
	56/F	Methylprednisolone, cyclosporin A			Clinical improvement
Abdo et al., 2014 [18]	81/M	Prednisone			Clinical improvement